Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Darolutamide (ODM-201) vs. ADT in Hormone Naive Prostate Cancer
NCT02972060Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2017
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Started Dec 2017; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02972060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972060.